trending Market Intelligence /marketintelligence/en/news-insights/trending/8reboBZM6s2vDggP4W2u9g2 content esgSubNav
In This List

Foamix seeks US FDA approval for acne drug

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Foamix seeks US FDA approval for acne drug

Foamix Pharmaceuticals Ltd. submitted an application seeking U.S. Food and Drug Administration approval for its acne drug FMX101.

The Israel-based company is seeking the regulator's nod for FMX101 as a therapy for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients aged 9 years and older.

The application is based on the results of two late-stage trials, called FX2014-05 and FX2017-22.